Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2009 1
2010 4
2011 4
2012 27
2013 35
2014 58
2015 50
2016 78
2017 76
2018 86
2019 85
2020 107
2021 102
2022 59
2023 69
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

768 results

Results by year

Filters applied: . Clear all
Page 1
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ. Tseng A, et al. Ann Pharmacother. 2017 Nov;51(11):1008-1022. doi: 10.1177/1060028017717018. Epub 2017 Jun 19. Ann Pharmacother. 2017. PMID: 28627229 Free PMC article. Review.
OBJECTIVE: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; and summarize antiretroviral and comedication interaction studies, with a focus on similarities and differences between ritonavir and cobic …
OBJECTIVE: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; an …
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED. Deeks ED. Drugs. 2018 Jul;78(10):1013-1024. doi: 10.1007/s40265-018-0934-2. Drugs. 2018. PMID: 29915897 Review.
Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza()) is the first protease inhibitor (PI)-based single-tablet regimen (STR) available for the treatment of adults and adolescents (aged 12 years) with HIV-1 infection. ...Over 48 weeks in phase 3 trials, darunavir/c …
Darunavir/cobicistat/emtricitabine/tenofovir AF (Symtuza()) is the first protease inhibitor (PI)-based single-tablet regimen (STR) av …
Darunavir/Cobicistat (Prezcobix).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. PMID: 27227212 Free Books & Documents. Review.
The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DR …
The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 8 …
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Greig SL, Deeks ED. Greig SL, et al. Drugs. 2016 Jun;76(9):957-68. doi: 10.1007/s40265-016-0586-z. Drugs. 2016. PMID: 27189707 Review.
With regard to establishing and/or maintaining virological suppression over 48 weeks in randomized, phase III trials, elvitegravir/cobicistat/emtricitabine/tenofovir AF was noninferior to elvitegravir/cobicistat/emtricitabine/tenofovir DF in antiretroviral therapy ( …
With regard to establishing and/or maintaining virological suppression over 48 weeks in randomized, phase III trials, elvitegravir/cobici …
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Sherman EM, Worley MV, Unger NR, Gauthier TP, Schafer JJ. Sherman EM, et al. Clin Ther. 2015 Sep 1;37(9):1876-93. doi: 10.1016/j.clinthera.2015.07.022. Epub 2015 Aug 25. Clin Ther. 2015. PMID: 26319088 Review.
PURPOSE: This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerability, drug interactions, and dosing and administration of cobicistat. METHODS: Searches of MEDLINE and International Pharmaceutical A …
PURPOSE: This article reviews the clinical pharmacology, pharmacodynamic and pharmacokinetic (PK) properties, clinical efficacy and tolerabi …
Darunavir/cobicistat once daily for the treatment of HIV.
Kakuda TN, Crauwels H, Opsomer M, Tomaka F, van de Casteele T, Vanveggel S, Iterbeke K, de Smedt G. Kakuda TN, et al. Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400. Expert Rev Anti Infect Ther. 2015. PMID: 25962100 Review.
Cobicistat is a more specific cytochrome P450 3A inhibitor than ritonavir without enzyme-inducing properties. This review describes the differing effects of cobicistat and ritonavir on metabolic enzymes, which explains their differing drug-drug interactions, and sum …
Cobicistat is a more specific cytochrome P450 3A inhibitor than ritonavir without enzyme-inducing properties. This review describes t …
Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
Nguyen T, McNicholl I, Custodio JM, Szwarcberg J, Piontkowsky D. Nguyen T, et al. AIDS Rev. 2016 Apr-Jun;18(2):101-11. AIDS Rev. 2016. PMID: 27196356 Review.
Recently, cobicistat was approved for the treatment of HIV-1 infection in treatment-naive adults as a component of a single-tablet regimen consisting of cobicistat-boosted elvitegravir plus emtricitabine and tenofovir disoproxil fumarate. ...To date, more studies ha …
Recently, cobicistat was approved for the treatment of HIV-1 infection in treatment-naive adults as a component of a single-tablet re …
Cobicistat: A case of mislabelled drug-drug interaction risk?
Burger DM, Calmy A, Marzolini C. Burger DM, et al. Br J Clin Pharmacol. 2020 May;86(5):834-836. doi: 10.1111/bcp.14262. Epub 2020 Mar 6. Br J Clin Pharmacol. 2020. PMID: 32144787 Free PMC article. No abstract available.
Cobicistat (Tybost) combinations for HIV.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2015 Nov 23;57(1482):159-60. Med Lett Drugs Ther. 2015. PMID: 26583606 Review. No abstract available.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) (Genvoya) Fixed-Dose Combination, Oral Tablet).
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov. PMID: 28121099 Free Books & Documents. Review.
The objective of this systematic review is to evaluate of the beneficial and harmful effects of the fixed-dose combination (FDC) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/COBI/FTC/TAF) for the treatment of human immunodeficiency virus type 1 (HIV- …
The objective of this systematic review is to evaluate of the beneficial and harmful effects of the fixed-dose combination (FDC) of elvitegr …
768 results